# Dr. Reddy’s Wins Tentative FDA Approval for Yeztugo Generic

By Riza Dagoc

Canonical URL: https://www.tokenpost.com/news/regulation/48116
Published: 2026-11-04T00:55:24.000Z
Updated: 2026-11-04T00:55:24.000Z
Section: Regulation

> The generic targets Gilead Sciences’ twice-yearly HIV prevention medicine.

Dr. Reddy’s Laboratories said Monday that the U.S. Food and Drug Administration tentatively approved its generic targeting Yeztugo, Gilead Sciences’ twice-yearly HIV prevention medicine.

Yeztugo is used for HIV prevention twice a year. The FDA action described by Dr. Reddy’s was tentative.